News for Aclaris Therapeutics, Inc. (ACRS)

WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( ACRS), a clinical-stage biopharmaceutical company focused on developing novel prod

Aclaris (ACRS) delivered earnings and revenue surprises of 68.75% and 313.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $9.2 million for Q4 2024, exceeding the estimated $2.11 million.Net Loss: $96.6 million for Q4 2024, a significant increase from $1.5 million in Q4 20

**media[552096]**

- Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bo

- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE)

WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( ACRS) (the ”œCompany” or ”œAclaris”), a clinical-stage biopharmaceutical comp

Burning Rock Biotech (BNR) experienced a significant stock drop of 5.02%, with shares priced at $6.25 and a trading volume of 4,410 shares. The stock's turnover

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( ACRS)(the ”œCompany” or ”œAclaris”), a clinical-stage biopharmaceutical compa

**media[482652]**

WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug

On November 18, 2024, Rock Springs Capital Management LP (Trades, Portfolio) executed a significant transaction involving Aclaris Therapeutics Inc. The firm add

On November 19, 2024, [Anand Mehra](https://www.gurufocus.com/insider/29172/anand-mehra), a Director at Aclaris Therapeutics Inc, purchased 666,666 shares of th

Cantor has upgraded Aclaris (ACRS) to overweight, citing the company's in-licensing of two drug candidates from China’s Biosion and concurrent equity raise. Read more here.

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting upgrades by Piper Sandler, BTIG, Jefferies and Leerink.

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by various factors, as well as...

Annette Insurance (AWH) experienced a significant stock drop, falling 6.19%. The stock is currently priced at $0.910 per share with a trading volume of 82,577 s

As Per SNS Insider, Alopecia Treatment Market Growth is Driven by Rising Demand for Hair Restoration Products, and Technological Advancements....